Paul VanderLaan - Dissemin

Dissemin is shutting down on January 1st, 2025

Language
Login

All papers authored by Paul VanderLaan

This paper is made freely available by the publisher.

2020 Tapan K. Biswas, Paul A. VanderLaan

ORCID

ORCID

, Ayelet Gonen, Paulette Krishack, Christoph J. Binder

ORCID

, Joseph L. Witztum

ORCID

, Godfrey S. Getz, Catherine A. Reardon

ORCID

CD1d Selectively Down Regulates the Expression of the Oxidized Phospholipid-Specific E06 IgM Natural Antibody in Ldlr−/− Mice

Download from doi.org

This paper was not found in any repository, but could be made available legally by the author.

Kartik Sehgal

ORCID

, Anushi Bulumulle, Heather Brody, Ritu R. Gill, Shravanti Macherla, Aleksandra Qilleri, Danielle C. McDonald, Cynthia R. Cherry, Meghan Shea

ORCID

, Mark S. Huberman, Paul A. VanderLaan

ORCID

, Glen J. Weiss, Paul R. Walker, Daniel B. Costa, Deepa Rangachari

Association of extended dosing intervals or delays in pembrolizumab-based regimens with survival outcomes in advanced non-small cell lung cancer

Upload

This paper was not found in any repository, but could be made available legally by the author.

2018 Paul A. VanderLaan

ORCID

ORCID

, Marcello DiStasio

ORCID

, Deepa Rangachari, Daniel B. Costa, Yael K. Heher

Molecular Testing Turnaround Time in Non–Small-Cell Lung Cancer: Monitoring a Moving Target

Upload

This paper is made freely available by the publisher.

Magda Bahcall, Mark M. Awad

ORCID

, Lynette M. Sholl, Frederick H. Wilson, Man Xu, Stephen Wang, Sangeetha Palakurthi, Jihyun Choi, Elena V. Ivanova, Giulia C. Leonardi, Bryan C. Ulrich, Cloud P. Paweletz, Paul T. Kirschmeier, Masayuki Watanabe, Hideo Baba and 10 other authors

Amplification of wild type KRAS imparts resistance to crizotinib in MET exon 14 mutant non-small cell lung cancer

Download from aacrjournals.org

Missing publications? Search for publications with a matching author name.